Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Tao LiWen-Yu YangTing-Ting LiuYao LiLu LiuXuan ZhengLei ZhaoFan ZhangYi HuPublished in: Technology in cancer research & treatment (2023)
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has successfully opened up a new model of targeted therapy. At present, proto-oncogene rearranged during transfection (RET) fusion gene is an important novel oncogenic driving target, and specific receptor tyrosine kinase inhibitors (TKIs) targeting RET fusion have been approved. This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- small cell lung cancer
- cancer therapy
- genome wide
- genome wide identification
- transcription factor
- drug delivery
- palliative care
- dna methylation
- bioinformatics analysis
- gene expression
- protein kinase
- label free
- loop mediated isothermal amplification